Reprogramming of TAMs via the STAT3/CD47-SIRPalpha axis promotes acquired resistance to EGFR-TKIs in lung cancer. Lu J, Li J, Lin Z, Li H, et al. Cancer Lett 2023;564:216205.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lu J, Li J, Lin Z, Li H, et al. Reprogramming of TAMs via the STAT3/CD47-SIRPalpha axis promotes acquired resistance to EGFR-TKIs in lung cancer. Cancer Lett 2023;564:216205.
PMID: 37146936